Search research articles
Contact Us
Filters
Showing results (21-30 of 51) with videos related to
Page
of 6
Sort By:
Biomaterials
|
March 22, 2016
Targeting inhibition of Foxp3 by a CD28 2'-Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy
Teresa Lozano, Mario Martínez Soldevilla, Noelia Casares, et al.
Expert Review of Vaccines
|
November 17, 2011
BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma
Helena Villanueva, Ascension Lopez-Diaz de Cerio, Susana Inoges, et al.
Iscience
|
February 2, 2026
Pharmacological perturbation of splicing elicits SMG1 reduction: Implications for cancer therapy
Martin Barainka, Angelina Zheleva, Angela Pérez-Cervera, et al.
Biomaterials
|
August 2, 2015
2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia
Mario Martinez Soldevilla, Helena Villanueva, Maurizio Bendandi, et al.
Gut
|
February 23, 2025
RNA-based therapies in liver metabolic diseases
Antonio Fontanellas, Pedro Berraondo, Francesco Urigo, et al.
Molecular Therapy. Nucleic Acids
|
August 22, 2022
A pan-tumor-siRNA aptamer chimera to block nonsense-mediated mRNA decay inflames and suppresses tumor progression
Daniel Meraviglia-Crivelli, Helena Villanueva, Ashwathi Puravankara Menon, et al.
Molecular Therapy. Nucleic Acids
|
June 26, 2020
Aptamers Against Live Targets: Is In Vivo SELEX Finally Coming to the Edge?
Mayte Sola, Ashwathi Puravankara Menon, Beatriz Moreno, et al.
The Journal of Clinical Investigation
|
December 7, 2007
Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice
James O McNamara, Despina Kolonias, Fernando Pastor, et al.
Current Topics in Medicinal Chemistry
|
March 31, 2011
Stem cell transplant and idiotypic vaccination for B-cell malignancies
Susana Inoges, Ascension Lopez-Diaz de Cerio, Antonia Sampol, et al.
Seminars in Oncology
|
August 31, 2015
Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS
Miguel F Sanmamed, Fernando Pastor, Alfonso Rodriguez, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 51) with videos related to
Sort By:
Page
of 6
Biomaterials
|
March 22, 2016
Targeting inhibition of Foxp3 by a CD28 2'-Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy
Teresa Lozano, Mario Martínez Soldevilla, Noelia Casares, et al.
Expert Review of Vaccines
|
November 17, 2011
BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma
Helena Villanueva, Ascension Lopez-Diaz de Cerio, Susana Inoges, et al.
Iscience
|
February 2, 2026
Pharmacological perturbation of splicing elicits SMG1 reduction: Implications for cancer therapy
Martin Barainka, Angelina Zheleva, Angela Pérez-Cervera, et al.
Biomaterials
|
August 2, 2015
2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia
Mario Martinez Soldevilla, Helena Villanueva, Maurizio Bendandi, et al.
Gut
|
February 23, 2025
RNA-based therapies in liver metabolic diseases
Antonio Fontanellas, Pedro Berraondo, Francesco Urigo, et al.
Molecular Therapy. Nucleic Acids
|
August 22, 2022
A pan-tumor-siRNA aptamer chimera to block nonsense-mediated mRNA decay inflames and suppresses tumor progression
Daniel Meraviglia-Crivelli, Helena Villanueva, Ashwathi Puravankara Menon, et al.
Molecular Therapy. Nucleic Acids
|
June 26, 2020
Aptamers Against Live Targets: Is In Vivo SELEX Finally Coming to the Edge?
Mayte Sola, Ashwathi Puravankara Menon, Beatriz Moreno, et al.
The Journal of Clinical Investigation
|
December 7, 2007
Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice
James O McNamara, Despina Kolonias, Fernando Pastor, et al.
Current Topics in Medicinal Chemistry
|
March 31, 2011
Stem cell transplant and idiotypic vaccination for B-cell malignancies
Susana Inoges, Ascension Lopez-Diaz de Cerio, Antonia Sampol, et al.
Seminars in Oncology
|
August 31, 2015
Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS
Miguel F Sanmamed, Fernando Pastor, Alfonso Rodriguez, et al.
Page
of 6